Neurexis Therapeutics: New Discoveries Could Revolutionize Treatment of Alzheimer's and Other Neurological Conditions

Results published in the journal Nature confirm critical role of Calcium Calmodulin Kinase II (CaMKII) enzyme Aurora, CO - Neurexis Therapeutics, a biotechnology company committed to reshaping the landscape of...

The Genomic Revolution: Unveiling Personalized Medicine's Investment Potential

In healthcare, a paradigm shift is underway – one that promises to transform healthcare as we know it. The emergence of personalized medicine, fueled by groundbreaking advancements in genomics and diagnostics, can save...

Exploring the Clinical Applications of Virtual Reality in Healthcare

Background: While most people think of virtual reality as a source of entertainment, there are potential clinical applications of virtual reality. In this article, we will explore some of the most promising clinical...

FDA Breakthrough Device Designation for High Impact Medical Devices

Within the VIC Tech portfolio, SFC Fluidics and Solenic Medical have both announced FDA Breakthrough Device designation. But what is FDA Breakthrough Device designation and what benefits does it provide? From a...

Cellia Science Awarded Phase I STTR Grant by National Institute of Biomedical Imaging and Bioengineering to Develop Instrument for Bone Marrow Aspiration Adequacy Assessment

This innovative use of Cellia’s core technology has the potential to improve the quality and reliability of bone marrow aspiration procedures.

VIC Tech Announces New Class of Fellows

The VIC Tech investment model is unique; it sources promising life science innovation directly from universities across the nation, allocating funding to form startup companies and advance these technologies to exit via...

SFC Fluidics Inc. Receives $2 Million SBIR Grant to Develop Groundbreaking Dual Hormone System for Diabetes Care

Next Generation Closed Loop System Designed for Broader Type I Diabetes Patient Population Fayetteville, AR - SFC Fluidics Inc., a medical device company focusing on drug delivery for treatment of Type 1 Diabetes, is...

VIC 2023 Mid-Year Report

Despite the difficult fundraising environment currently existing nationwide, VIC’s portfolio of companies made impressive progress in the first half of 2023.

Solaris Vaccines Awarded Funding from NIH to Develop Novel Influenza Vaccine using SolaVAX™ Platform

This NIAID SBIR will evaluate an innovative approach for producing superior vaccines more quickly and cost-effectively. FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that it has received a Small Business...

Solenic Medical, Inc. Announces $5.1M Series A Funding Round Led by Johnson & Johnson Innovation – JJDC, Inc.

Solenic accelerates their mission to treat patients suffering from acute or chronic prosthetic joint infections (PJI). ADDISON, TEXAS – Solenic Medical, developer of a device that uses alternating magnetic fields (AMF)...

The Advantages of Investing in Venture Creation Firms Like VIC Tech

In the world of early stage investing, traditional venture capital funds have long been the go-to option for investors seeking exposure to high-growth opportunity companies. However, a different investment model is...

Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager

Thank you for taking the time to speak with us, Dr. Clark. Please tell us about your education and professional experience.

Nob Hill Therapeutics Selected for Featured Poster Presentation at Respiratory Innovation Summit

Albuquerque, NM, May 19, 2023 – Nob Hill Therapeutics (NHT), an inhalation technology company, today announced that it has been selected to be a featured poster presentation at the ATS 2023 Respiratory Innovation Summit...

VIC Foundry Awarded Phase I SBIR Grant from the National Institutes of Health

NIH Grant is to Develop a Portable Sample Preparation Device for Concentration and Recovery of Bacterial Contaminants

Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)

A promising approach for preventing cognitive and behavioral impairment following ischemia Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II...

Solaris Vaccines Adds Izabela Ragan as Director of Research and Development for the SolaVAX™ Platform

FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development. The Company is developing a...

Intellectual Property Landscape Analysis Using Free Patent Databases

For an investor seeking a decision on whether or not to invest in an innovation-based startup, there are numerous factors they need to take into consideration. Some of the most important questions that need to be...

Due Diligence for Life Science Investments

Investing in a life science startup can be a lucrative opportunity, but it requires careful evaluation to weigh the potential reward against the level of risk. Members of VIC Tech's affiliated VIC Investor Network...

From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.

I have been very fortunate to have had a varied and diverse career accelerating the development of life science innovation, including therapeutics, vaccines, medical devices, diagnostics, analytical instruments,...

Cellia Science Awarded National Institutes of Health Phase I SBIR Funding

Fayetteville, AR - Cellia Science, a point-of-care hematology company, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Heart, Lung, and Blood...

VIC Fellows Spotlight: Matthew Leming, PhD

The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovations from global sources. We are pleased to highlight the...

VIC 2022 Annual Report Executive Summary

2022 was a highly productive year for VIC and our portfolio companies. Click Here to download the Annual Report Executive Summary or view it below.

VIC Tech Adds Chantell Preston to Board of Directors

Bringing a proven track record in healthcare operations, innovation, and investing. FAYETTEVILLE, AR- VIC Technology Venture Development is pleased to announce the appointment of Chantell Preston, who brings 20+ years...

A Letter from our CEO

As CEO of VIC Tech, I am fortunate to have the opportunity to review exciting new life science technologies on an ongoing basis and regularly speak with life science thought leaders, inventors, investors, and large...


VIC Tech Announces New Class of Fellows
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
Solenic Medical, Inc. Announces $5.1M Series A Funding Round Led by Johnson & Johnson Innovation – JJDC, Inc.
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.